Literature DB >> 8543939

Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis.

H M Jansen1, A T Willemsen, L G Sinnige, A M Paans, J M Hew, E J Franssen, A M Zorgdrager, J Pruim, J M Minderhoud, J Korf.   

Abstract

Multiple sclerosis (MS) is an immune-mediated disease of the white matter in the brain that can have a progressive course. However, the progression of relapsing-remitting (RR) MS into relapsing-progressive (RP) MS might represent a more fundamental change in disease activity, i.e. decay of vulnerable neurons and oligodendrocytes. In RP-MS, this may imply that the major loss of brain tissue structure is caused by a combination of demyelination and cellular loss, both of which are likely to cause disability in MS. We used the PET isotope cobalt-55 (Co) as a calcium (Ca) tracer to visualize brain tissue damage, based on the fact that Ca influx is essential in both cell death and T-lymphocyte activation in MS. The aim of this study was to determine whether Co-PET detects any RP-MS lesions and, if so, to assess any correlation with the progression rate (PR) of the disease and with MS lesions as detected by MRI. Seven RP-MS patients (Poser) with EDSS > 4.0 (Kurtzke) and 7 healthy controls underwent MRI (Miller, Barkhof) and Co-PET. Comparison of both image modalities was made by merging. Co-PET lesion frequency was assessed and correlated with the PR of the disease. Co-PET demonstrated significantly more lesions in the MS brain than in the healthy brain, both periventricular and cortical. Every single MRI lesion could be retrieved as a Co-PET lesion. The Co-PET lesion frequency correlated significantly with PR. Our pilot study possibly suggests Co-PET as a tool in estimating disease activity in RP-MS.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543939     DOI: 10.1016/0022-510x(95)00139-s

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets.

Authors:  H F Valdovinos; R Hernandez; S Graves; P A Ellison; T E Barnhart; C P Theuer; J W Engle; W Cai; R J Nickles
Journal:  Appl Radiat Isot       Date:  2017-09-06       Impact factor: 1.513

2.  Cobalt-55 positron emission tomography in traumatic brain injury: a pilot study.

Authors:  H M Jansen; J van der Naalt; A H van Zomeren; A M Paans; L Veenma-van der Duin; J M Hew; J Pruim; J M Minderhoud; J Korf
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

Review 3.  Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".

Authors:  George Firth; Julia E Blower; Joanna J Bartnicka; Aishwarya Mishra; Aidan M Michaels; Alex Rigby; Afnan Darwesh; Fahad Al-Salemee; Philip J Blower
Journal:  RSC Chem Biol       Date:  2022-04-11

Review 4.  PET radiometals for antibody labeling.

Authors:  Eduardo Aluicio-Sarduy; Paul A Ellison; Todd E Barnhart; Weibo Cai; Robert Jerry Nickles; Jonathan W Engle
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

5.  Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors.

Authors:  Helena Wållberg; Sara Ahlgren; Charles Widström; Anna Orlova
Journal:  Mol Imaging Biol       Date:  2009-06-26       Impact factor: 3.488

6.  High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.

Authors:  Bogdan Mitran; Helge Thisgaard; Ulrika Rosenström; Johan Hygum Dam; Mats Larhed; Vladimir Tolmachev; Anna Orlova
Journal:  Contrast Media Mol Imaging       Date:  2017-08-10       Impact factor: 3.161

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.